News Release

Influenza vaccine immune response in patients with high-risk cardiovascular disease

JAMA Cardiology

Peer-Reviewed Publication

JAMA Network

About The Study: High-dose influenza vaccine elicited a more robust humoral response in patients with heart failure or prior myocardial infarction enrolled in the INVESTED randomized clinical trial, with no association between seroconversion status and the risk for cardiopulmonary hospitalizations or all-cause mortality. Vaccination to prevent influenza remains critical in high-risk populations. 

Authors: Scott D. Solomon, M.D., of Brigham and Women’s Hospital and Harvard Medical School in Boston, and Orly Vardeny, Pharm.D., M.S., of the University of Minnesota in Minneapolis, are the corresponding authors.

To access the embargoed study: Visit our For The Media website at this link 


Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: This study is being released to coincide with presentation at the American College of Cardiology’s Annual Scientific Session. 

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.